Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
PROJECT SUMMARY / ABSTRACT – OVERALL
Prostate cancer is the second leading cause of cancer deaths of men in the United States and places a
significant health burden on society. The overarching goal of the UCSF Prostate Cancer SPORE is to address
this burden by reducing the morbidity and mortality associated with prostate cancer, through leveraging a deep
understanding of the disease to translate biological findings into clinical impact. The SPORE team will approach
this mission with transdisciplinary research that is highly collaborative and translational, through four specific
aims: A) Investigate molecular drivers of aggressive prostate cancer; B) Develop biomarkers to guide treatment
of patients with advanced prostate cancer; C) Target therapeutic resistance in metastatic castration resistant
prostate cancer (mCRPC), which is the lethal manifestation of advanced disease; and D) Accelerate translational
research across the spectrum of prostate cancer.
To address these aims, the UCSF Prostate SPORE proposes three scientific projects, each investigating
aggressive prostate cancer from a mechanistic, biomarker, and therapeutic perspective:
Project 1: Combination immunotherapy with radioligand therapy for metastatic prostate cancer
Project 2: Investigating Clinical and Biological Implications of a Novel Hypermethylated Subtype of mCRPC
Project 3: Deciphering the Role of the Translational Oncogenic Program in Prostate Cancer
These proposed studies will be aided by horizontal collaborations with other Prostate SPORES, NCI initiatives,
and molecular diagnostics companies, as well as vertical collaborations with the National Clinical Trials Network
(NCTN), DOD Prostate Cancer Clinical Trials Consortium (PCCTC), and pharmaceutical companies, among
other organizations. Additionally, these projects will be complemented by strong, ongoing institutional
commitments of money and space, well-resourced Career Enhancement and Developmental Research
Programs, and three cores: Administration, Biostatistics/Bioinformatics, and Pathology/Tissue.
The infrastructure outlined under this SPORE application is designed to encourage and promote translation of
innovative, impactful ideas by supporting promising new projects, providing access to critical resources for
bench-to-bedside transitions, sponsoring interdisciplinary collaborations, and providing an effective framework
for mentoring/nurturing the next generation of translational scientists. By bringing together a diverse and multi-
disciplinary group of investigators, this Prostate Cancer SPORE will accelerate highly impactful translational
research with the potential to significantly improve clinical outcomes for men with aggressive prostate cancer.
Public Health Relevance Statement
PROJECT NARRATIVE – OVERALL
The UCSF Prostate Cancer SPORE seeks to reduce the morbidity and mortality associated with prostate cancer
by leveraging a deep understanding of the disease to translate biological findings into clinical impact. In this
SPORE application, three translational projects focus on developing novel biomarkers and highly effective
therapies for patients with aggressive prostate cancer. These projects are highly collaborative with respect to
the multidisciplinary nature and expertise of the Co-Leaders.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AccelerationAddressAndrogen ReceptorBioinformaticsBiologicalBiological MarkersBiologyBiometryCaliforniaCancer Center Support GrantCancer EtiologyCancer PatientCastrate sensitive prostate cancerCellsCessation of lifeClassificationClinicalClinical InvestigatorClinical TrialsCollaborationsCombination immunotherapyComprehensive Cancer CenterDevelopmentDirect CostsDiseaseDisease ProgressionFamilyFosteringFundingFutureGenerationsGeneticGenomicsGoalsGrantGrowth and Development functionHealthHypermethylationInfrastructureInstitutionLaboratory ScientistsLife Support CareMalignant neoplasm of prostateMentorsMentorshipMetastatic Prostate CancerMissionMolecularMorbidity - disease rateNCI-Designated Cancer CenterNational Cancer ProgramNational Clinical Trials NetworkNatureOncogenicOutcomePathologyPatientsPeer ReviewPharmacologic SubstancePre-Clinical ModelProcessProductivityProstatePublishingReceptor SignalingRecordsRefractory DiseaseResearchResearch PersonnelResearch Project GrantsResourcesRoleSan FranciscoScientistSocietiesSpecialized Program of Research ExcellenceTherapeuticTissuesTranslatingTranslational ResearchTranslationsUnited StatesUniversitiesadvanced diseaseadvanced prostate cancerandrogen deprivation therapyandrogen independent prostate cancerbench to bedsidebench-to-bedside translationcancer clinical trialcareerdesigneffective therapyimprovedinhibitorinnovationinterdisciplinary collaborationmenmolecular diagnosticsmolecular markermolecular subtypesmortalitymultidisciplinarynew therapeutic targetnext generationnovelnovel markernovel therapeuticspersonalized medicineprogramsradioligandresponsetargeted treatmenttherapy developmenttherapy resistanttranslational scientistvirtual
No Sub Projects information available for 1P50CA275741-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1P50CA275741-01A1
Patents
No Patents information available for 1P50CA275741-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1P50CA275741-01A1
Clinical Studies
No Clinical Studies information available for 1P50CA275741-01A1
News and More
Related News Releases
No news release information available for 1P50CA275741-01A1
History
No Historical information available for 1P50CA275741-01A1
Similar Projects
No Similar Projects information available for 1P50CA275741-01A1